Sustained Low Clinical Event Rates in Real‐World Patients Receiving Everolimus‐Eluting Coronary Stent System from a Large, Prospective, Condition of Approval Study: 2‐Year Clinical Outcomes from the XIENCE V^® USA Study

Low event rates observed at 1 year were maintained through 2 years. Despite the increased number of patients who discontinued dual antiplatelet therapy by 2 years, the ST rate remained consistently low, and <1% at 2 years due to low VLST occurrence. These results demonstrate continued safety and effectiveness of the XIENCE V everolimus-eluting stent in a highly complex, real-world patient population through 2 years.